Literature DB >> 9010013

Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease.

P K Morrish1, G V Sawle, D J Brooks.   

Abstract

We have investigated regional changes in dopamine metabolism within the basal ganglia with clinical progression of idiopathic Parkinson's disease, using coregistration of [18F]dopa-PET and MRI images and comparing six normal subjects with 15 Parkinson's disease patients in a cross-sectional study. We have demonstrated that [18F]dopa metabolism in the dorsal putamen is reduced to almost 50% of normal both caudally and rostrally early in the disease whilst the ventral putamen is not significantly affected. With progression of symptoms there is loss of dopa metabolism from the ventral putamen, the ventrocaudal putamen in advance of the ventrorostral putamen. Throughout the disease the ventrorostral putamen is relatively preserved; even in the most advanced group [18F]dopa uptake is reduced here by only 30%. We conclude that the progression of Parkinson's disease is associated with a focal process affecting only the dorsal putamen in its early (and preclinical) phase then affecting the ventral putamen with increasing disease severity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9010013     DOI: 10.1093/brain/119.6.2097

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  25 in total

1.  Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease.

Authors:  Ruth Djaldetti; Therese A Treves; Ilan Ziv; Eldad Melamed; Yair Lampl; Mordechai Lorberboym
Journal:  Neurol Sci       Date:  2009-06-05       Impact factor: 3.307

Review 2.  Evidence from clinical trials: can we do better?

Authors:  Andrew D Siderowf
Journal:  NeuroRx       Date:  2004-07

Review 3.  Neuroimaging and transcranial ultrasonography in Parkinson's disease.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

Review 4.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

5.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

6.  Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.

Authors:  Catherine L Gallagher; Terrence R Oakes; Sterling C Johnson; Moo K Chung; James E Holden; Barbara B Bendlin; Donald G McLaren; Guofan Xu; Robert J Nickles; Robert Pyzalski; Onofre DeJesus; W Douglas Brown
Journal:  Mov Disord       Date:  2011-03-29       Impact factor: 10.338

Review 7.  Presynaptic dopamine in schizophrenia.

Authors:  Nobumi Miyake; Judy Thompson; Mette Skinbjerg; Anissa Abi-Dargham
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

Review 8.  Functional neuroimaging in Parkinson's disease.

Authors:  Martin Niethammer; Andrew Feigin; David Eidelberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

9.  A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.

Authors:  Catherine L Gallagher; Sterling C Johnson; Barbara B Bendlin; Moo K Chung; James E Holden; Terrence R Oakes; Benjamin R Brooks; Richard A Konopacki; Selami Dogan; James H Abbs; Guofan Xu; Robert J Nickles; Robert W Pyzalski; Onofre T Dejesus; W Douglas Brown
Journal:  Brain Imaging Behav       Date:  2011-09       Impact factor: 3.978

10.  Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes.

Authors:  Yilong Ma; Chengke Tang; Thomas Chaly; Paul Greene; Robert Breeze; Stanley Fahn; Curt Freed; Vijay Dhawan; David Eidelberg
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.